Nuvectis Pharma (NVCT) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed OmniAb (OABI) over the past year, gaining 232.1% versus a gain of 166.3%. OmniAb is the larger company by market cap ($677.5 million vs $657.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | OABI |
|---|---|---|
| Share price | $20.13 | $4.66 |
| Market cap | $657.12M | $677.52M |
| 1-day change | -0.79% | +2.19% |
| YTD return | +168.74% | +151.89% |
| 1-year return | +232.08% | +166.29% |
| 5-year return | — | -53.26% |
| EPS (TTM) | $-1.31 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $5.43 |
| 52-week low | $5.55 | $1.30 |
| Distance from 52-week high | -31.24% | -14.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +75.86% | +88.84% |
| Average volume | 217.91K | 1.45M |
| Shares outstanding | 32.64M | 145.39M |
| Employees | 16 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed OABI by 65.8 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
NVCT vs OABI FAQ
Which is bigger, Nuvectis Pharma or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $677.52M compared with $657.12M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, NVCT or OABI?
NVCT returned +232.08% over the past 12 months, compared with +166.29% for OABI (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and OmniAb in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Nuvectis Pharma and Biotechnology: Commercial Physical & Biological Resarch for OmniAb.